iCAD to Highlight Promising Research on Potential of its AI Algorithm to More Accurately Identify and Personalize Breast Cancer Risk at SIIM 2024

June 26, 2024

https://www.globenewswire.com/news-release/2024/06/26/2904445/0/en/iCAD-to-Highlight-Promising-Research-on-Potential-of-its-AI-Algorithm-to-More-Accurately-Identify-and-Personalize-Breast-Cancer-Risk-at-SIIM-2024.html

NASHUA, N.H., June 26, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, today announced it will highlight new research demonstrating the efficacy of its ProFound AI Risk algorithm in breast cancer risk assessment compared to traditional models at the upcoming Society for Imaging Informatics in Medicine (SIIM) Annual Meeting. The company will also highlight its recently launched ProFound Cloud, an advanced software-as-a-service (SaaS) platform that offers medical providers a cost-effective, secure, and scalable solution for accessing and deploying the latest ProFound Breast Health Suite of AI solutions.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.